This was the stock's second consecutive day of losses.

INmune Bio saw its stock surge 75% in after-hours trading Thursday after disclosing plans to unveil topline results from its Phase 2 Alzheimer’s trial on Monday. The company will present findings from ...

Upstream Bio to present novel data on verekitug's potency at EAACI Congress 2025, targeting respiratory inflammatory diseases.

G RI Bio has announced encouraging six-week interim safety outcomes from the ongoing Phase IIa trial of the small molecule ...

IOVA's ASCO update reiterates the value of Amtagvi in melanoma, but upcoming data in lung cancer and endometrial cancer in H2 ...

Brii Bio Presents Late-Breaking Data from Its Ongoing Phase 2 ENSURE Study at EASL Congress 2025, Suggesting BRII-179's Role in Advancing Higher HBsAg Loss Brii Bio Presents Late-Breaking Data ...

Intelligent Bio Solutions to present Pharmacokinetic study data at Association for Diagnostics and Laboratory Medicine 2025 Clinical Lab Expo: New York Tuesday, July 15, 2025, 15: ...

A memo that purports to summarize a meeting held by members of a biotech trade group suggests deep concern about RFK Jr.’s ...

Adaptive Computation LLC Assessed “Awardable” for DARPA[JR1] ERIS Marketplace – Adaptive Computation LLC, a leading provider ...

T is a Novel, Non-Aromatizing Androgen, Offering the Benefits of Testosterone Without Converting to Estradiol Addressing a ...